

World Journal of *Gastroenterology*

World J Gastroenterol 2017 July 7; 23(25): 4473-4660



**EDITORIAL**

- 4473 Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars

Hakizimana A, Ahmed I, Russell R, Wright M, Afzal NA

REVIEW

- 4480 Expression and role of nuclear receptor coregulators in colorectal cancer

Triki M, Lapierre M, Cavailles V, Mokdad-Gargouri R

- 4491 Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

Ponziani FR, Zocco MA, D'Aversa F, Pompili M, Gasbarrini A

MINIREVIEWS

- 4500 Localization and role of metabotropic glutamate receptors subtype 5 in the gastrointestinal tract

Ferrigno A, Berardo C, Di Pasqua LG, Siciliano V, Richelmi P, Vairetti M

ORIGINAL ARTICLE**Basic Study**

- 4508 Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury

Takasu C, Vaziri ND, Li S, Robles L, Vo K, Takasu M, Pham C, Farzaneh SH, Shimada M, Stamos MJ, Ichii H

- 4517 Enhanced electrogastrography: A realistic way to salvage a promise that was never kept?

Poscente MD, Mintchev MP

- 4529 Glutamine prevents oxidative stress in a model of portal hypertension

Zabot GP, Carvalhal GF, Marroni NP, Licks F, Hartmann RM, da Silva VD, Fillmann HS

- 4538 Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment

Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruiz J, Ruiz Extremera Á, Salmerón J

- 4548 Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis

Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, Brezina J, Wohl P, Spicak J, Drastich P

- 4559 Anti-inflammatory and anti-apoptotic effects of rosuvastatin by regulation of oxidative stress in a dextran sulfate sodium-induced colitis model

Shin SK, Cho JH, Kim EJ, Kim EK, Park DK, Kwon KA, Chung JW, Kim KO, Kim YJ

- 4569 miR-29a promotes hepatitis B virus replication and expression by targeting SMARCE1 in hepatoma carcinoma

Wu HJ, Zhuo Y, Zhou YC, Wang XW, Wang YP, Si CY, Wang XH

Retrospective Cohort Study

- 4579 Management and outcome of hepatocellular adenoma with massive bleeding at presentation

Klomphehouwer AJ, de Man RA, Thomeer MGJ, Ijzermans JNM

Retrospective Study

- 4587 Chronic hepatitis B, nonalcoholic steatohepatitis and physical fitness of military males: CHIEF study

Chen YJ, Chen KW, Shih YL, Su FY, Lin YP, Meng FC, Lin F, Yu YS, Han CL, Wang CH, Lin JW, Hsieh TY, Li YH, Lin GM

- 4595 Comparison of short- and long-term outcomes of laparoscopic vs open resection for gastric gastrointestinal stromal tumors

Ye X, Kang WM, Yu JC, Ma ZQ, Xue ZG

Observational Study

- 4604 Functional lipidomics in patients on home parenteral nutrition: Effect of lipid emulsions

Pironi L, Guidetti M, Verrastro O, Iacona C, Agostini F, Pazzeschi C, Sasdelli AS, Melchiorre M, Ferreri C

- 4615 Cryptogenic multifocal ulcerous stenosing enteritis: Radiologic features and clinical behavior

Hwang J, Kim JS, Kim AY, Lim JS, Kim SH, Kim MJ, Kim MS, Song KD, Woo JY

- 4624 Partners of patients with ulcerative colitis exhibit a biologically relevant dysbiosis in fecal microbial metacommunities

Chen GL, Zhang Y, Wang WY, Ji XL, Meng F, Xu PS, Yang NM, Bo XC

Randomized Controlled Trial

- 4632 Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs

Harvie RM, Chisholm AW, Bisanz JE, Burton JP, Herbison P, Schultz K, Schultz M

EVIDENCE-BASED MEDICINE

- 4644 Anti-apoptotic effect of banhasasim-tang on chronic acid reflux esophagitis

Shin MR, An HJ, Seo BI, Roh SS

SYSTEMATIC REVIEWS

- 4654** Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review

Fiore M, Maraolo AE, Gentile I, Borgia G, Leone S, Sansone P, Passavanti MB, Aurilio C, Pace MC

Contents

World Journal of Gastroenterology
Volume 23 Number 25 July 7, 2017

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Ludovico Abenavoli, MD, MSc, PhD, Associate Professor, Health Sciences, University Magna Graecia, Campus Germaneto, Viale Europa, 88100 Catanzaro, Italy

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Fen-Fen Zhang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
July 7, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Basic Study

Glutamine prevents oxidative stress in a model of portal hypertension

Gilmara Pandolfo Zabet, Gustavo Franco Carvalhal, Norma Possa Marroni, Francielli Licks, Renata Minuzzo Hartmann, Vinícius Duval da Silva, Henrique Sarubbi Fillmann

Gilmara Pandolfo Zabet, Gustavo Franco Carvalhal, Henrique Sarubbi Fillmann, Department of Surgery, School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS 90610-000, Brazil

Norma Possa Marroni, Francielli Licks, Renata Minuzzo Hartmann, Department of Gastroenterology, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS 90035-903, Brazil

Vinícius Duval da Silva, Department of Pathology, School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS 90610-000, Brazil

Author contributions: Zabet GP and Fillmann HS designed and performed the research, analysed the data and wrote the paper; Carvalhal GF analysed the data and wrote the paper; Marroni NP designed the research; Licks F and Hartmann RM performed the research; da Silva VD analysed the pathological data; all authors read and approved the final manuscript.

Institutional review board statement: The study was reviewed and approved by the School of Medicine, Pontifical Catholic University of Rio Grande do Sul.

Institutional animal care and use committee statement: Animal care was in compliance with the normative resolution 04/97 of the Research and Ethics Committee of the Health Research Group and Graduate Teaching Hospital of Porto Alegre.

Conflict-of-interest statement: There are no conflicts of interest.

Data sharing statement: The authors declare that they compared all data from the study.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and

the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Gilmara Pandolfo Zabet, Ms, Sci, Department of Surgery, School of Medicine, Pontifical Catholic University of Rio Grande do Sul; Duque de Caxias Street, 1012/19, Porto Alegre, RS 90610-000, Brazil. gilmrapandolfo@terra.com.br
Telephone: +55-51-999357780
Fax: +55-51-34787000

Received: February 2, 2017

Peer-review started: February 9, 2017

First decision: February 23, 2017

Revised: March 3, 2017

Accepted: June 12, 2017

Article in press: June 12, 2017

Published online: July 7, 2017

Abstract

AIM

To evaluate the protective effects of glutamine in a model of portal hypertension (PH) induced by partial portal vein ligation (PPVL).

METHODS

Male Wistar rats were housed in a controlled environment and were allowed access to food and water *ad libitum*. Twenty-four male Wistar rats were divided into four experimental groups: (1) control group (SO) - rats underwent exploratory laparotomy; (2) control + glutamine group (SO + G) - rats were subjected to laparotomy and were treated intraperitoneally with glutamine; (3) portal hypertension group (PPVL) - rats were subjected to PPVL; and (4) PPVL + glutamine group (PPVL + G) - rats were treated intraperitoneally

with glutamine for seven days. Local injuries were determined by evaluating intestinal segments for oxidative stress using lipid peroxidation and the activities of glutathione peroxidase (GPx), endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) after PPVL.

RESULTS

Lipid peroxidation of the membrane was increased in the animals subjected to PH ($P < 0.01$). However, the group that received glutamine for seven days after the PPVL procedure showed levels of lipid peroxidation similar to those of the control groups ($P > 0.05$). The activity of the antioxidant enzyme GPx was decreased in the gut of animals subjected to PH compared with that in the control group of animals not subjected to PH ($P < 0.01$). However, the group that received glutamine for seven days after the PPVL showed similar GPx activity to both the control groups not subjected to PH ($P > 0.05$). At least 10 random, non-overlapping images of each histological slide with $200 \times$ magnification ($44 \text{ pixel} = 1 \mu\text{m}$) were captured. The sum means of all areas, of each group were calculated. The mean areas of eNOS staining for both of the control groups were similar. The PPVL group showed the largest area of staining for eNOS. The PPVL + G group had the second highest amount of staining, but the mean value was much lower than that of the PPVL group ($P < 0.01$). For iNOS, the control (SO) and control + G (SO + G) groups showed similar areas of staining. The PPVL group contained the largest area of iNOS staining, followed by the PPVL + G group; however, this area was significantly smaller than that of the group that underwent PH without glutamine ($P < 0.01$).

CONCLUSION

Treatment with glutamine prevents gut mucosal injury after PH in rats.

Key words: Portal hypertension; Endothelial nitric oxide synthase; Glutamine; Glutathione peroxidase; Inducible nitric oxide synthase; Lipid peroxidation

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Portal hypertension (PH) is characterized by an increased portal pressure gradient. The progressive increase in portal pressure leads to the formation of portosystemic shunts and intestinal hypoxia. Many enzymes have been implicated in this process, among them endothelial nitric oxide synthase and inducible nitric oxide synthase. Some substances, such as glutamine, have been studied as protective agents against oxidative stress. In an experimental model of PH induced by partial portal vein ligation, we have found that glutamine reduced lipid peroxidation and preserved intestinal glutathione peroxidase activity, suggesting a protective role of this amino acid in the setting of PH.

Zabot GP, Carvalhal GF, Marroni NP, Licks F, Hartmann RM, da Silva VD, Fillmann HS. Glutamine prevents oxidative stress in a model of portal hypertension. *World J Gastroenterol* 2017; 23(25): 4529-4537 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i25/4529.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i25.4529>

INTRODUCTION

Portal hypertension (PH) is a clinical entity defined by a haemodynamic increased portal pressure gradient, directly related to the portal blood flow and vascular resistance^[1,2]. Anatomically, the causes of PH can be classified as pre-hepatic (portal vein thrombosis or splenic), intra-hepatic (cirrhosis) and post-hepatic (Budd-Chiari syndrome)^[3].

PH triggers disorders of the gastrointestinal tract, compromising the function of the small intestine. Gastrointestinal bleeding is present in 80%-90% of patients with PH due to the progressive dilatation of the vessels, which rupture and lead to haemorrhage^[4]. Such a high bleeding rate points to the need to study the pathophysiology of PH to minimize its consequences. The partial ligation model of the portal vein is the model most widely used to study pre-hepatic PH; it was developed by Sikuler in 1985, and several experimental studies have shown that, in animals, partial portal vein ligation (PPVL) produces abnormalities that are equivalent to those of PH in humans^[5].

The development of hyper dynamic circulation can cause structural changes in the intestinal wall as well as spontaneous bacterial infections and sepsis^[6]. The increase in splanchnic vascular resistance and venous flow leads to congestion in the portal system, causing an intermittent intestinal hypo perfusion^[7]. Oxidative stress damages the integrity of the intestinal mucosa and leads to lipid peroxidation^[8,9]. Likewise, there is an increased production of nitric oxide (NO) in this hyper dynamic state, producing nitrosative stress^[10]. NO is the main mediator of cytotoxic immune cells and plays a messenger/modulatory role in many important biological processes^[11]. However, it is highly toxic, especially in cases of oxidative stress and in situations of antioxidant system deficiency^[12]. The physiological and pathophysiological effects of the nitric oxide isoforms [endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS)] are related to their concentration levels^[13]. When operating at low concentrations, these isoforms behave as messengers and cell protection factors (antioxidants), interacting with transition metals and other free radicals. Under high concentrations and upon forming dinitrogen trioxide (N_2O_3) or peroxyxynitrite (ONOO), NO behaves as an active species of nitrogen, responsible for numerous cytotoxic actions in a framework known as nitrosative stress^[14]. A high NO concentration was

observed in PH, this increase being intimately related to the development of hyper dynamic circulation and oxidative stress^[15].

To protect against the damage posed by oxidative stress, we need a system to prevent the formation of free radicals and neutralize oxidative damage, a function performed by antioxidants. The enzymatic system is one of the most important defence systems because it catalytically removes free radicals and other reactive species. Superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) are some of the most prominent antioxidant enzymes. The peroxidase GPx enzyme is characteristically located in the cytosol and mitochondrial matrix^[16-18].

Similar to the enzymes involved in removing free radicals, there are other substances with antioxidant properties capable of preventing oxidative chain reactions, such as those involved in lipid peroxidation (LPO). These substances are known as non-enzymatic antioxidant defences^[19,20].

Glutamine is the most commonly found free amino acid in plasma, acting on oxygen-free radicals and playing an important role in attenuating inflammatory bowel disease^[21]. It is used for hepatic synthesis of urea, for renal ammoniogenesis and for gluconeogenesis and also serves as the main respiratory fuel for many cell types^[8]. Thus, it is vital to the regulation of the intracellular oxidative balance^[22].

The progression of different diseases is triggered by oxidative stress. In PH, it promotes the development of collateral circulation. Thus, antioxidant therapy appears to be a promising strategy to minimize the complications of PH^[15].

The objectives of this study were to evaluate the effects of glutamine in rats with pre-hepatic PH submitted to an experimental model of PPVL, to assess LPO and determine the activity of the enzyme GTx in the intestine. Additionally, we aimed to quantify the expression of the enzymes eNOS and iNOS in the intestine through immunohistochemistry.

MATERIALS AND METHODS

Ethics

Animal care was performed in compliance with the normative resolution 04/97 of the Research and Ethics Committee of the Health Research Group and Graduate Teaching Hospital of Porto Alegre (Hospital de Clínicas de Porto Alegre-HCPA)^[23].

Animals

Twenty-four male Wistar rats weighing between 250 and 350 grams, were used from the State Foundation for Research and Production in Health (FEPPS-RS). The animals were divided into 4 groups of 6. During the experiment, the animals were kept in plastic boxes of 47 cm × 34 cm × 18 cm lined with wood, in a cycle of 12 h light/dark and temperature between 20 and

25 °C. Water and feed are given *ad libitum*.

Surgical procedures

After trichotomy, rats were anaesthetized with ketamine and xylazine solution [45 mg/kg intraperitoneally (ip)]. After midline laparotomy, the bowel loops were removed gently and were covered with gauze moistened with saline, and then, the portal vein was isolated. A 20G needle was placed on the portal vein and tied with 3.0 silk sutures. Subsequently, the needle was gently removed, and the occurrence of portal vein thrombosis was noted^[5]. Sham-operated (SO) control animals underwent the same procedures but without partial ligation of the portal vein. After surgery, the animals were treated with glutamine or saline solution, depending on the group. Glutamine was administered beginning on day 8 after surgery, intraperitoneally, at a dosage of 0.75 g/kg for 7 d^[12]. Control animals received vehicle (saline, 0.9% NaCl) in a volume of 0.6 mL intraperitoneally for the same period. At the end of the experiments, intestinal segments (10 cm) were removed for histological examination and biochemical studies.

Experimental groups

Rats were randomly allocated into the following groups: (1) control group (SO): rats were subjected to the simulation of surgery and vehicle administration (NaCl) ($n = 6$); (2) control + glutamine group (SO + G): rats were subjected to the simulation of surgery and glutamine administration ($n = 6$); (3) PH group (PPVL): rats were subjected to PPVL and vehicle administration (NaCl) ($n = 6$); (4) PPVL + glutamine group (PPVL + G): rats were subjected to PPVL and glutamine administration ($n = 6$).

Assessment of lipid peroxidation

Thiobarbituric acid reactive substances: Tissue samples were placed in test tubes, and solutions were added in the following order: 0.75 mL of 10% trichloroacetic acid (TCA), 0.25 mL of homogenate, 0.5 mL of 0.67% thiobarbituric acid (TBA), and 0.25 mL of distilled water. Thiobarbituric acid reactive substances (TBARS) were measured by heating the homogenate with thiobarbituric acid and then measuring the consequent formation of a coloured product in a spectrophotometer at 535 nm. The coloration is due to the presence of malondialdehyde and other substances from biological lipid peroxidation^[24].

GTx activity

The determination of selenium glutathione peroxidase was based on the method of Guntzler Flohé and consisted of measuring the nicotinamide adenine dinucleotide phosphate dehydrogenase (NADPH) consumption rate in a system containing total glutathione (GSH), wherein the oxidation is recorded spectrophotometrically at a wavelength of 340 nm. The

GPx activity can be studied by measuring the NADPH consumption rate in a system containing GSH^[25].

This technique consists of determining the activity of the enzyme spectrophotometrically by measuring the rate of oxidation of NADPH in a reaction.

To this end, 2.7 mL of phosphate regulating solution of Na⁺ and K⁺ (100 mmol/L, pH 7.0) was placed in a quartz cuvette with 50 µL of NADPH (10 mmol/L), 150 µL of butylhydroperoxide (BOOH) (10 mmol/L) and 50 µL of glutathione reductase (12 U/mL). The mixture was read for 1 min and was identified as the baseline, followed by the addition of 50 µL of GSH (100 mmol/L) and 50 mL of homogenate. The samples were incubated at 25 °C for 5 min and then absorbance was read at 340 nm. The activity was expressed in nmol/min/mg protein^[25].

Evaluation of eNOS and iNOS

For the preparation of the slides and subsequent immunohistochemical analysis, 3-µm-thick sections were prepared using a microtome (Leica SM 2000R, Germany). The sections were placed on slides pre-treated with HistoGrip (Zymed, United States) and were left in the oven at 60 °C for 24 h.

The sections were then deparaffinized by incubation with xylene for 10 min three times, followed by rehydration with a sequence of decreasing concentrations of ethanol (absolute, 90%, 80% and 70%) for 3 min per dilution. Next, the sections were washed three times in distilled water.

Antigen retrieval was performed by heating in a pTLINK platform (DAKO) and then treating the slides for 40 min at 98 °C with the Envision Flex high pH antigen retrieval solution (DAKO). Immediately thereafter, the slides were washed with PBS buffer at a pH of 7.2. Endogenous peroxidase was blocked by incubation in a solution of 3% H₂O₂ in methanol for two 15-min intervals, followed by washing three times with PBS buffer at a pH of 7.2.

The sections were then incubated using a Sequenza (Thermo Shandon, United States) immunostaining station, were left for 2 h at room temperature and then were diluted with the dilution solution (Antibody Diluent with background reducing components, Dako, United States) and the following antibodies: Anti-eNOS (Thermo Scientific, PA3-031A, United States) 1:800, anti-iNOS (PA5-16855 Thermo Scientific, United States) 1:800. After incubation with the primary antibody, the sections were washed three times with PBS buffer at a pH of 7.2. For the amplification of the antigen-antibody reaction for anti-eNOS, we used the HRP Envision Flex System (Dako, United States) in accordance with the manufacturer's recommendations. Next, the slides were washed with PBS buffer at a pH of 7.2 and were incubated with diaminobenzidine solution (Dako Liquid DAB Substrate Chromogen System, United States) for 5 min. After washing in distilled water, the slides were counterstained with

Harris haematoxylin for 1 min and were washed with water until complete removal of the dye, followed by incubation in a 37-mmol/L ammonia solution for 15 s. Finally, the slides were dehydrated in absolute ethanol (four 2-min incubations) and were treated twice with xylene for 5 min. The slides were then mounted with Entellan synthetic medium (Merck, Germany)^[20,26,27].

Analysis of digital images

We used a digital analysis system composed of a Zeiss Axioskop 40 microscope (Oberkochen, Germany) with Neofluar lenses connected by a Roper Scientific video camera (Media Cybernetics, Rockville, United States) to a computer with an Image Capture Pro kit (Media Cybernetics, Rockville, MD, United States) capture card. Image-Pro Plus version 7.0 (Media Cybernetics, Rockville, United States) was used to analyse the digital images. Images were captured in the TIFF (True Image File Format) format without compression by the same examiner with the same light intensity pattern for all photos. Images were captured of at least fifteen random, non-overlapping fields for each histological slide at 200 × magnification (44 pixel = 1 µm). The hot spot method was used to select fields on slides with focal positivity for the markers. Colour selection was performed interactively by three trained observers and was then applied to all samples by the automated digital image analysis system. The initial area considered was 0.01 cm.

Statistical analysis

Quantitative data were initially described as the means and SE. For comparison of the groups, one-way analysis of variance (ANOVA) was used, followed by the SNK post hoc test (Student-Newman-Keuls). The level of significance for the experiment was *P* = 0.05. Data were analysed using SPSS software version 22.0. A biomedical statistician performed the statistical review.

RESULTS

Evaluation of lipid peroxidation

Oxidative stress, quantified by gut membrane lipid peroxidation was increased in the group of animals subjected to PPVL (*P* < 0.01). On the other hand, animals that received glutamine for seven days after the procedure exhibited levels of lipid peroxidation similar to those of the control groups (animals not subjected to PPVL and animals receiving glutamine without PPVL). These levels were also significantly different from those of the group of animals that was submitted solely to PPVL (*P* < 0.01; Figure 1).

GTx activity

The activity of GTx was decreased in the gut of animals subjected to PPVL compared with that of animals not subjected to PPVL (*P* < 0.01; Figure 2). Importantly,




Figure 1 Lipid peroxidation (thiobarbituric acid reactive substances). TBARS: Thiobarbituric acid reactive substances; SO: Control group; PPVL: Partial portal vein ligation; G: Glutamine.




Figure 2 Glutathione peroxidase. SO: Control group; PPVL: Partial portal vein ligation; G: Glutamine; GPx: Glutathione peroxidase.

the group that received glutamine for seven days after PPVL showed similar GTx activity to that of groups without PPVL. The difference in GTx activity in animals subjected to PPVL and in those that received glutamine after PPVL ($P < 0.05$), suggests that glutamine is a protective factor for PH.

Evaluation of eNOS

For digital analysis of the images, the program Image-Pro Plus version 7.0 (Media Cybernetics, Rockville, United States) was used. They were captured in the True Image File Format (TIFF) format, with at least ten fields, without random overlap, for each histological slide at $200 \times (44 \text{ pixel} = 1 \mu\text{m})$. Slides with focal positivity for the markers were selected by the hot spot method. The initial area considered was 0.01 cm. The sum of the stained areas was calculated for each group. The control (SO) and control + G (SO + G) groups presented with similar areas of staining. The PPVL group presented the largest area. The second group with larger staining areas was the PPVL + G, but with values much lower than those of the PPVL group,




Figure 3 Immunohistochemical expression of endothelial nitric oxide synthase. SO: Control group; PPVL: Partial portal vein ligation; G: Glutamine; eNOS: Endothelial nitric oxide synthase.

resembling the area found in the control groups with and without glutamine. These results were statistically significant ($P < 0.01$). These results are shown in Figures 3 and 4.

Evaluation of iNOS

Figures 5 and 6 show the immunohistochemical expression of iNOS. The control (SO) and control + G (SO + G) groups presented with similar areas of staining ($P > 0.05$). Regarding eNOS, the PPVL group also presented the largest stained area. The second group with a larger staining area was the PPVL + G, again with values much lower than those of the PPVL group. These results were also statistically significant ($P < 0.01$).

DISCUSSION

Glutamine promotes intracellular oxidative balance^[28]. It is a precursor of glutathione, one of the most important non-enzymatic cellular antioxidants, and is the most abundant free amino acid in plasma, acting on oxygen-free radicals^[29].

Other researchers have used the PPVL model to study pre-hepatic PH^[5]. Our work demonstrates that glutamine treatment exerts important protective effects in pre-hepatic PH in an animal model. We have shown that after PPVL glutamine: (1) reduced oxidative stress determined by the lipid peroxidation of the intestinal mucosa; (2) maintained levels of GTx activity; and (3) reduced the expression of eNOS and iNOS.

We have observed greater levels of lipid peroxidation in the group of animals that underwent PPVL. Glutamine significantly decreased lipid peroxidation in the PPVL model. Schimpl *et al*^[8] evaluated pre-hepatic PH with a model of common bile duct ligation (CBDL). They evaluated the effects of glutamine and allopurinol on bacterial translocation in PH and obstructive jaundice. These authors concluded that, in PH and common bile duct ligation (CBDL) in rats, there was significant




Figure 4 Digital images of the immunohistochemical expression of endothelial nitric oxide synthase (photomicrography, $\times 200$). A: SO; B: SO + G; C: PPVL; D: PPVL + G. SO: Control group; PPVL: Partial portal vein ligation; G: Glutamine.




Figure 5 Immunohistochemical expression of inducible nitric oxide synthase. SO: Control group; PPVL: Partial portal vein ligation; G: Glutamine; iNOS: Inducible nitric oxide synthase.

bacterial translocation, ileal mucosal lipid peroxidation, and neutrophil derived myeloperoxidase (MPO) activity. Bacterial translocation, ileal mucosal malondialdehyde (MDA) concentrations and MPO activities were significantly reduced by the combined use of allopurinol and glutamine.

Huang *et al.*^[30] studied the oxidative stress related to intrahepatic PH after ligation of the bile duct in rats. They identified an increase in the MDA levels in plasma as well as reduced levels of plasma GTx. We have found reduced levels of GTx activity in animals submitted to PPVL compared with controls

(SO and SO + G). When glutamine was administered intraperitoneally to animals submitted to PPVL, there was a less pronounced reduction if GTx activity levels. Rodríguez-Vilarrupla *et al.*^[17] stressed the importance of antioxidants as enzymatic systems in PH syndrome. The effects of glutamine on eNOS activity were already investigated Marques *et al.*^[22]; however, these authors have used a model of PH gastropathy. They have also evaluated the activity of the nitric oxide (eNOS) by immunohistochemistry. In their study, lipid peroxidation and NO were significantly increased in PPVL, but the addition of glutamine has attenuated eNOS expression^[22]. Oxidative stress was also evidenced by Gonzales *et al.*^[31] in a pre-hepatic PPVL rat model, through an increased concentration of TBARS. Additionally, these authors have shown a decrease in the antioxidant enzymes SOD, CAT and glutathione peroxidase (GTx). Moreover, they studied the antioxidant role of haem oxygenase-1 (HO-1) and suggested a beneficial role of HO-1 overexpression.

eNOS favours the decrease of blood pressure and assists in the inhibition of platelet aggregation. iNOS forms NO induced by certain cytotoxins, being closely related to defensive body processes^[14]. In our study, the PH group (PPVL) showed the largest area of staining for eNOS. The PPVL + G group had the second highest amount of stained areas, but with a mean value much lower than that of the PH group ($P < 0.05$). For iNOS, the control (SO) and control + G (SO + G) groups showed similar areas of staining. The




Figure 6 Digital images of the immunohistochemical expression of inducible nitric oxide synthase (photomicrography, $\times 200$). A: SO; B: SO + G; C: PPVL; D: PPVL + G. SO: Control group; PPVL: Partial portal vein ligation; G: Glutamine; iNOS: Inducible nitric oxide synthase.

PH group (PPVL) contained the largest area of iNOS staining, followed by the PPVL + G group; however, this area was significantly lower than that of the group that underwent PH without glutamine (PPVL).

Jalan *et al.*^[32] tested the hypothesis that ammonia modulates human hepatic stellate cell activation *in vitro* and *in vivo*, in a BDL model, using L-ornithine phenylacetate. This substance significantly reduced the plasmatic levels of ammonia and portal pressure, which was associated with increased eNOS activity^[32].

Iwakiri *et al.*^[14] stated that eNOS and iNOS have different roles; most commonly, eNOS prevents the occurrence of disease whereas iNOS favours its progress.

Kajita *et al.*^[33] observed that iNOS expression in vascular resident macrophages contributed to the circulatory dysfunction of splanchnic vascular smooth muscle contractions in PH rats^[33]. Xu *et al.*^[34], in a study with male Sprague-Dawley rats submitted to intra-hepatic PH induced by the injection of CCl₄, noted that iNOS contributes to the haemodynamic alterations of PH secondary to increased levels of NO^[34].

Oxidative stress is also responsible for hepatic encephalopathy. Pilar Carbonero-Aguilar *et al.*^[35], suggest that it may be resultant from increased ammonia concentration in the brain.

Arias *et al.*^[36], using an experimental model through the triple portal vein ligation method, demonstrated, for the first time, a relationship between inflammation, astrocyte damage and neurons and cerebral metabolic compromise.

The use of antioxidants in the prevention or treatment of various diseases related to oxidative stress seems to be a viable alternative in the attempt to minimize or reverse damage. Glutamine was initially used prophylactically in patients undergoing radiotherapy, resulting in a decreased incidence and decreased severity of actinic enteritis^[37]. This substance was most extensively investigated in relation to the oxidative stress caused by exercise. Cruzat *et al.*^[38] showed that, in exhaustive exercise, there is a significant reduction in serum glutamine. This decrease is accompanied by a significant increase in the inflammatory activity and oxidative stress levels measured by the lipid peroxidation rate. Glutamine has also been beneficial as a nutritional supplement in severely debilitated patients, such as those with multiple trauma or in those undergoing major surgery^[39,40]. Antioxidant therapy improves the prognosis and reduces the overall complication rates in debilitated patients^[41]. Tang *et al.*^[42] utilized TPN containing glutamine and recombinant human growth hormone in the postoperative care of patients after PH surgery. They found that this supplementation enhanced immune function, modulated the inflammatory response, and prevented the intestinal membrane atrophy.

This is the first publication describing the role of glutamine in the intestinal oxidative stress in an animal model of PPVL.

In conclusion, the present study demonstrates that intraperitoneally administration of glutamine

at a dose of 0.75 g/kg during 7 d, starting on the 8th postoperative day after PPVL, prevented lipid peroxidation and maintained GTx levels. The expression of eNOS and iNOS were reduced upon intraperitoneal glutamine during the 7 d after PPVL in rats. Our work confirms the findings of previously published experimental research on glutamine as a protective factor in murine models of PH. Additional research is necessary to ascertain the benefits of glutamine as protective element against intestinal disorders secondary to PH in humans.

ACKNOWLEDGMENTS

To the Pontifical Catholic University of Rio Grande do Sul, in particular to the Graduate Program in Medicine and Health Sciences, for the opportunity to carry out this study and have made available a scholarship.

COMMENTS

Background

Portal hypertension (PH) is often secondary to the obstruction of the intra- or extra-hepatic portal flow. The progressive increase in pressure in the portal system leads to dilation of the blood vessels, with consequent formation of porto-systemic shunts. The development of hyperdynamic circulation can cause structural changes in the intestinal wall and lipid peroxidation as well as oxidative stress. The physiological and pathophysiological effects of nitric oxide isoforms are related to their concentration levels. Glutamine has been investigated as a potential preventive agent against damage caused by inflammatory processes caused by oxidative agents.

Research frontiers

Being the most abundant amino acid in the plasma, glutamine has many roles including the regulation of macrophage activity, the modulation of reactive oxygen species, the hepatic synthesis of urea, renal ammoniogenesis, and gluconeogenesis, serving also as fuel for many cell types.

Innovations and breakthroughs

The first studies with glutamine were in patients undergoing radiotherapy, when there was a decreased incidence and severity of actinic enteritis associated with its use. It was also observed that glutamine plays a major role in the immune defence barrier of the intestinal mucosa through its participation in the formation of immunoglobulins, especially IgA. Furthermore, it was demonstrated that glutamine decreases the inflammatory enterocolitis induced by methotrexate and reduces bacterial translocation in animals with abdominal sepsis. These data demonstrate that glutamine prevents lipid peroxidation after partial portal vein ligation (PPVL) in a murine model.

Applications

This study suggests that glutamine reduces oxidative stress by decreasing lipid peroxidation and by preserving glutathione peroxidase (GTx) levels. The immunohistochemical expression of endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) were reduced upon intraperitoneal administration of glutamine for seven days starting on the eighth postoperative day after PPVL in rats.

Terminology

PH: a clinical entity defined by a haemodynamically increased portal pressure gradient that is directly related to the portal blood flow and vascular resistance. Lipid peroxidation: oxidative stress that causes an alteration in cell membrane permeability that favours bacterial translocation and the activation of the inflammatory response. GTx: an antioxidant enzyme that catalytically removes free radicals and other active oxidative species. eNOS and iNOS: isoforms of

nitric oxide, which is a mediator of cytotoxic immune cells that have messenger/modulator roles in many important biological processes.

Peer-review

It is a well-written paper. The current work evaluates the protective effects of glutamine in a model of PH induced by PPVL.

REFERENCES

- 1 **Bosch J**, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. *J Hepatol* 2008; **48** Suppl 1: S68-S92 [PMID: 18304681 DOI: 10.1016/j.jhep.2008.01.021]
- 2 **Kim MY**, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. *Korean J Hepatol* 2010; **16**: 347-352 [PMID: 21415576 DOI: 10.3350/kjhep.2010.16.4.347]
- 3 **Miñano C**, Garcia-Tsao G. Clinical pharmacology of portal hypertension. *Gastroenterol Clin North Am* 2010; **39**: 681-695 [PMID: 20951924 DOI: 10.1016/j.gtc.2010.08.015]
- 4 **Majid S**, Azam Z, Shah HA, Salih M, Hamid S, Abid S, Jafri W. Factors determining the clinical outcome of acute variceal bleed in cirrhotic patients. *Indian J Gastroenterol* 2009; **28**: 93-95 [PMID: 19907958 DOI: 10.1007/s12664-009-0034-z]
- 5 **Sikuler E**, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. *Am J Physiol* 1985; **248**: G618-G625 [PMID: 4003545 DOI: 10.1590/s0102-67202013000300010]
- 6 **Hernández-Guerra M**, García-Pagán JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. *J Clin Gastroenterol* 2005; **39**: S131-S137 [PMID: 15758648 DOI: 10.1097/01.mcg.0000155513.17715.f7]
- 7 **Bosch J**, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. *Gastroenterol Clin North Am* 1992; **21**: 1-14 [PMID: 1568769 DOI: 10.1111/j.1478-3231.2011.02579]
- 8 **Schimpl G**, Pesendorfer P, Steinwender G, Feierl G, Ratschek M, Höllwarth ME. Allopurinol and glutamine attenuate bacterial translocation in chronic portal hypertensive and common bile duct ligated growing rats. *Gut* 1996; **39**: 48-53 [PMID: 8881808 DOI: 10.1136/gut.39.1.48]
- 9 **Pijls KE**, Jonkers DM, Elamin EE, Masclee AA, Koek GH. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. *Liver Int* 2013; **33**: 1457-1469 [PMID: 23879434 DOI: 10.1111/liv.12271]
- 10 **Kanwar S**, Kubes P, Tepperman BL, Lee SS. Nitric oxide synthase activity in portal-hypertensive and cirrhotic rats. *J Hepatol* 1996; **25**: 85-89 [PMID: 8836906 DOI: 10.1016/S0168-8278(96)80332-1]
- 11 **Röth E**, Hejjel L, Jaberansari M, Jancso G. The role of free radicals in endogenous adaptation and intracellular signals. *Exp Clin Cardiol* 2004; **9**: 13-16 [PMID: 19641690]
- 12 **Halliwell B**. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. *Plant Physiol* 2006; **141**: 312-322 [PMID: 16760481 DOI: 10.1104/pp.106.077073]
- 13 **Cerqueira NF**, Hussni CA, Yoshida WB, Sequeira JL, Padovani CR. Effects of pentoxifylline and n-acetylcysteine on injuries caused by ischemia and reperfusion of splanchnic organs in rats. *Int Angiol* 2008; **27**: 512-521 [PMID: 19078915]
- 14 **Iwakiri Y**, Kim MY. Nitric oxide in liver diseases. *Trends Pharmacol Sci* 2015; **36**: 524-536 [PMID: 26027855 DOI: 10.1016/j.tips.2015.05.001]
- 15 **Fernando B**, Marley R, Holt S, Anand R, Harry D, Sanderson P, Smith R, Hamilton G, Moore K. N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. *Hepatology* 1998; **28**: 689-694 [PMID: 9731560 DOI: 10.1002/hep.510280314]
- 16 **Batinić-Haberle I**, Rebouças JS, Spasojević I. Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. *Antioxid Redox Signal* 2010; **13**: 877-918 [PMID: 20511111 DOI: 10.1089/ars.2010.3917]

- 20095865 DOI: 10.1089/ars.2009.2876]
- 17 **Rodríguez-Vilarrupla A**, Bosch J, García-Pagán JC. Potential role of antioxidants in the treatment of portal hypertension. *J Hepatol* 2007; **46**: 193-197 [PMID: 17161493 DOI: 10.1016/j.jhep.2006.11.008]
 - 18 **Closa D**, Folch-Puy E. Oxygen free radicals and the systemic inflammatory response. *IUBMB Life* 2004; **56**: 185-191 [PMID: 15230345 DOI: 10.1080/15216540410001701642]
 - 19 **Moreira AJ**, Fraga C, Alonso M, Collado PS, Zettler C, Marroni C, Marroni N, González-Gallego J. Quercetin prevents oxidative stress and NF-kappaB activation in gastric mucosa of portal hypertensive rats. *Biochem Pharmacol* 2004; **68**: 1939-1946 [PMID: 15476665 DOI: 10.1016/j.bcp.2004.07.016]
 - 20 **Licks F**, Marques C, Zetler C, Martins MI, Marroni CA, Marroni NP. Antioxidant effect of N-acetylcysteine on prehepatic portal hypertensive gastropathy in rats. *Ann Hepatol* 2014; **13**: 370-377 [PMID: 24756013]
 - 21 **Curi R**, Lagranha CJ, Doi SQ, Sellitti DF, Procopio J, Pithon-Curi TC, Corless M, Newsholme P. Molecular mechanisms of glutamine action. *J Cell Physiol* 2005; **204**: 392-401 [PMID: 15795900 DOI: 10.1002/jcp.20339]
 - 22 **Marques C**, Mauriz JL, Simonetto D, Marroni CA, Tuñón MJ, González-Gallego J, Marrón NP. Glutamine prevents gastric oxidative stress in an animal model of portal hypertension gastropathy. *Ann Hepatol* 2011; **10**: 531-539 [PMID: 21911895]
 - 23 **Goldim JR**, Raymundo MM. Pesquisa em saúde e direitos dos animais. 2nd ed. Porto Alegre: HCPA, 1997
 - 24 **Buege JA**, Aust SD. Microsomal lipid peroxidation. *Methods Enzymol* 1978; **52**: 302-310 [PMID: 672633 DOI: 10.1016/S0076-6879(78)52032-6]
 - 25 **Flohe L**, Günzler WA, Schöck HH. Glutathione peroxidase: a selenoenzyme. *FEBS Lett* 1973; **32**: 132-134 [PMID: 4736708 DOI: 10.1016/0014-5793(73)80755-0]
 - 26 **Gaffey MJ**, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. *Am J Surg Pathol* 1992; **16**: 593-599 [PMID: 1599037 DOI: 10.1097/00000478-199206000-00007]
 - 27 **Zhao X**, Deng B, Xu XY, Yang SJ, Zhang T, Song YJ, Liu XT, Wang YQ, Cai DY. Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis. *World J Gastroenterol* 2013; **19**: 6069-6076 [PMID: 24106408 DOI: 10.3748/wjg.v19.i36.6069]
 - 28 **Calder PC**, Yaqoob P. Glutamine and the immune system. *Amino Acids* 1999; **17**: 227-241 [PMID: 10582122 DOI: 10.1007/BF01366922]
 - 29 **Gianotti L**, Alexander JW, Gennari R, Pyles T, Babcock GF. Oral glutamine decreases bacterial translocation and improves survival in experimental gut-origin sepsis. *JPEN J Parenter Enteral Nutr* 1995; **19**: 69-74 [PMID: 7658604 DOI: 10.1177/014860719501900169]
 - 30 **Huang YT**, Hsu YC, Chen CJ, Liu CT, Wei YH. Oxidative-stress-related changes in the livers of bile-duct-ligated rats. *J Biomed Sci* 2003; **10**: 170-178 [PMID: 12595753 DOI: 10.1007/BF02256052]
 - 31 **Gonzales S**, Perez MJ, Perazzo JC, Tomaro ML. Antioxidant role of heme oxygenase-1 in prehepatic portal hypertensive rats. *World J Gastroenterol* 2006; **12**: 4149-4155 [PMID: 16830363 DOI: 10.3748/wjg.v12.i26.4149]
 - 32 **Jalan R**, De Chiara F, Balasubramaniyan V, Andreola F, Khetan V, Malago M, Pinzani M, Mookerjee RP, Rombouts K. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. *J Hepatol* 2016; **64**: 823-833 [PMID: 26654994 DOI: 10.1016/j.jhep.2015.11.019]
 - 33 **Kajita M**, Murata T, Horiguchi K, Iizuka M, Hori M, Ozaki H. iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats. *Am J Physiol Heart Circ Physiol* 2011; **300**: H1021-H1031 [PMID: 21193589 DOI: 10.1152/ajpheart.00563.2009]
 - 34 **Xu J**, Cao H, Liu H, Wu ZY. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension. *Hepatobiliary Pancreat Dis Int* 2008; **7**: 503-508 [PMID: 18842497]
 - 35 **Carbonero-Aguilar P**, Diaz-Herrero M, Campo J, Cremades O, Romero-Gómez M, Bautista J. Hyperammonemia induced oxidative stress in cirrhotic rats without promoting differential protein expression in the brain cortex: A 2D-DIGE analysis. *Adv Biosci Biotechnol* 2012; **3**: 1116-1123 [DOI: 10.4236/abb.2012.38137]
 - 36 **Arias N**, Méndez M, Gómez-Lázaro E, Azpiroz A, Arias JL. Main target of minimal hepatic encephalopathy: Morphophysiological, inflammatory and metabolic view. *Physiol Behav* 2015; **149**: 247-254 [PMID: 26079568 DOI: 10.1016/j.physbeh.2015.06.019]
 - 37 **Klimberg VS**, Souba WW, Dolson DJ, Salloum RM, Hautamaki RD, Plumley DA, Mendenhall WM, Bova FJ, Khan SR, Hackett RL. Prophylactic glutamine protects the intestinal mucosa from radiation injury. *Cancer* 1990; **66**: 62-68 [PMID: 2354410]
 - 38 **Cruzat VF**, Rogero MM, Tirapegui J. Effects of supplementation with free glutamine and the dipeptide alanyl-glutamine on parameters of muscle damage and inflammation in rats submitted to prolonged exercise. *Cell Biochem Funct* 2010; **28**: 24-30 [PMID: 19885855 DOI: 10.1002/cbf.1611]
 - 39 **Heyland DK**, Dhaliwal R, Day AG, Muscedere J, Drover J, Suchner U, Cook D; Canadian Critical Care Trials Group. REDucing Deaths due to OXidative Stress (The REDOXS Study): Rationale and study design for a randomized trial of glutamine and antioxidant supplementation in critically-ill patients. *Proc Nutr Soc* 2006; **65**: 250-263 [PMID: 16923310 DOI: 10.1079/PNS2006505]
 - 40 **Demirkan A**, Savaş B, Melli M. Endotoxin level in ischemia-reperfusion injury in rats: effect of glutamine pretreatment on endotoxin levels and gut morphology. *Nutrition* 2010; **26**: 106-111 [PMID: 19596185 DOI: 10.1016/j.nut.2009.04.010]
 - 41 **Nathens AB**, Neff MJ, Jurkovich GJ, Klotz P, Farver K, Ruzinski JT, Radella F, Garcia I, Maier RV. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. *Ann Surg* 2002; **236**: 814-822 [PMID: 12454520 DOI: 10.1097/00000658-200212000-00014]
 - 42 **Tang ZF**, Ling YB, Lin N, Hao Z, Xu RY. Glutamine and recombinant human growth hormone protect intestinal barrier function following portal hypertension surgery. *World J Gastroenterol* 2007; **13**: 2223-2228 [PMID: 17465506 DOI: 10.3748/wjg.v13.i15.2223]

P- Reviewer: Arias JL, Hashimoto N **S- Editor:** Gong ZM
L- Editor: A **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

